Wegovy Solution for injection
PDF Leaflet Revision Date: N/A
Clinical Summary
Quick overview from the medicine insert
Indication
Weight management in adults and adolescents with obesity or overweight with comorbidities.
Dosage (summary)
Adults: Start at 0.25 mg weekly, increase to 2.4 mg over 16 weeks. Adolescents: Same schedule as adults.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy or breastfeeding; use contraception in women of childbearing potential.
Key Drug Interactions
- Caution with oral medications requiring rapid absorption
- Increased risk of hypoglycaemia with insulin or sulfonylureas
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2
- Hypersensitivity to semaglutide
Common side effects
- Nausea
- Diarrhoea
- Vomiting
- Constipation
- Headache
Counselling Points
- Monitor for signs of thyroid tumors
- Stay hydrated
- Report any severe gastrointestinal symptoms
Serious warnings
- Risk of thyroid C-cell tumors
- Acute pancreatitis
- Dehydration due to gastrointestinal effects
Important Disclaimer
The Wegovy Solution for injection professional information leaflet below is the property of Novo Nordisk and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
